It warrants further investigation
Protocol details: Initial phase dose: 20-30 ml per day Initial phase route: IV infusion (diluted in 100-250 ml saline) Initial duration: 14-21 days Maintenance dose: 10 ml per day Maintenance duration: 14 additional days Infusion time: 30-60 minutes (never rapid bolus at these doses) Expected timeline based on TBI trial data: Day 7-10: Improved neurological scores on GCS Day 21: Favorable GCS in treated patients with contusion and diffuse axonal injury Week 12: Significant cognitive improvement (CASI scores) in mild TBI Month 6: 67% achieved good outcomes (GOS 3-5) in moderate to severe cases Protocol 3: combination approach with donepezil Goal: Maximize cognitive benefit in established dementia through complementary mechanisms
That means they are not subject to GMP or the quality control requirements that come with it
TB-4 (full-length, 43 aa) moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring
Contraindications AOD-9604 is not appropriate for everyone
then, the mesendodermal aggregates were hepatically specified for 5 days, resulting in the expression of AFP , CEBPa , HNF4, PROX1 , TBX3 , and TTR coinciding with decreased expression of DE markers such as HHEX , SOX17 and GATA4 (Supplementary Fig
